Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 410Lung Neoplasms 261Small Cell Lung Carcinoma 75Colorectal Neoplasms 71Breast Neoplasms 52Ovarian Neoplasms 48Neoplasms 48Melanoma 48Pancreatic Neoplasms 45Neoplasm Metastasis 38Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 31Prostatic Neoplasms 28Head and Neck Neoplasms 27Esophageal Neoplasms 26Carcinoma, Renal Cell 26Endometrial Neoplasms 25Colonic Neoplasms 24Triple Negative Breast Neoplasms 23Uterine Cervical Neoplasms 22Urinary Bladder Neoplasms 21Carcinoma, Hepatocellular 21Mesothelioma, Malignant 14Mesothelioma 14Sarcoma 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Lung Diseases 13Liver Neoplasms 13Carcinoma, Transitional Cell 13Thyroid Neoplasms 12

Interventions

patritumab deruxtecan 1durvalumab 1Pemetrexed 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Non-Small Cell Lung Cancer Metastatic × Thoracic × 30 days × Clear all
NCT04163432 2026-05-19

STAGGER

University of Utah

Phase 2 Active not recruiting
43 enrolled 12 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT04619004 2026-05-14

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Daiichi Sankyo

Phase 2 Active not recruiting
277 enrolled 16 charts
Thoracic

Non-Small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡